Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1427-1431

  Patlakas, George ^a   Bouros, Demosthenes ^a   Tsantekidou Pozova, Sofia ^a   Koukourakis, Michael I ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Dept of Radiotherapy Oncology ^*  (Greece)

Author keywords

Docetaxel; Gemcitabine; Liposomal doxorubicin; NSCLC

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHYLPREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROPISETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; ESOPHAGITIS; FEMALE; FEVER; FLUID RETENTION; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; INJECTION SITE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MYCOSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; VOMITING;

AGED; ALOPECIA; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; STOMATITIS; TAXOIDS;

EID: 17444414229     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bunn PA Jr: Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20(18 Suppl): 23S-33S, 2002.
2. Waters JS and O'Brien ME: The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer 57: 481-490, 2002.
3. Paesmans M: Benefits of chemotherapy for quality of life in patients with advanced non small cell lung cancer. Curr Opin Oncol 14: 389-393, 2002.
4. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N and Giaccone G: European Organization for Research and Treatment of Cancer Lung Cancer Group: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3017, 2003.
5. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L and Tonato M: Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-91, 2002
6. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M and Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003.
7. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P and Vlachonikolis I: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-84, 2001.
8. Gabizon A, Tzemach D, Mak L, Bronstein M and Horowitz AT: Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10: 539-548, 2002.
9. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Grigoratou T, Palamidas P, Kouroussis C, Mavroudis D, Kakolyris S, Giannakakis T and Vlachonikolis J: Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4): S47-51, 2001.
10. Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM and Whang-Peng J: Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25: 509-512, 2002.
11. Popa IE, Stewart K, Smith FP and Rizvi NA: A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced non small cell lung carcinoma. Cancer 95: 1714-1719, 2002.
12. Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R and Nishiwaki Y: Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol 52: 19-24, 2003.
13. Hong RL and Tseng YL: Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91: 1826-33, 2001.
14. Caponigro F, Comella P, Budillon A, Bryce J, Avallone A, De Rosa V, Ionna F and Comella G: Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann Oncol 11: 339-342, 2000.
15. Gabizon A, Catane R, Uziely B Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
16. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N and Helidonis ES: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
17. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G and Bahlitzanakis N: Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87: 385-392, 2002.
18. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D and Glick J: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101-2112, 1996.
19. Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C, Georgakopoulos G, Panoussaki K, Karageorgis P and Throuvalas N: Clinical Radiation Oncololgy Hellenic Group: A randomized phase III trial of radiation treatment +- amifostine in patients with advanced stage lung cancer. Int J Radiat Oncol Biol Phys 51: 915-922, 2001.
20. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL and Cox JD: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 55: 1369-1377, 2004.